| Answers |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Investing > How to Build a Fortune in the Stock Markets - Learn How Use Volatility to Score Enormous Returns |
|
Answers - How to Build a Fortune in the Stock Markets - Learn How Use Volatility to Score Enormous Returns
Volatility Equals Risk is an Investment Myth Propagated by Global Investment Firms Most financial consultants when they speak of your investment portfolio mention a low beta as a positive attribute. In fact, you will hear many wealth managers stress the need of having a beta close to 1.00. Beta, in simple te According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product rms, is the measure of a stock’s or portfolio’s volatility as compared to the volatility of the stock market index as a whole. So if you owned a stock with a beta of 1.30, it would be about 30% more volatile then the market index. I’ve often seen the beta coefficient used interchangeably to define the risk inherent in a port ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in olio. For example, people will say if the beta of your portfolio is much greater than 1.00 then you have an aggressive, risky portfolio and if the beta of your portfolio is much less than 1.00 then you have a conservative portfolio. This is nonsense. First of all, the beta coefficient is determined using the domestic stock m lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. rket index as the constant. For example in the U.S., the beta coefficient will be determined by comparing the volatility of a stock or stock portfolio versus the volatility of the S&P 500 index. But we are already starting off on the wrong foot by doing so because nobody should have a stock portfolio that is concentrated in t here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe eir domestic market only. Chances are that many of the best performing stocks you will own will be in a foreign stock market. So what if the beta of your stock portfolio is high compared to your domestic market index but low compared to regional market index? What does that mean? You Can Not Build Wealth in Your Port d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro olio Without Volatility Or what if the situation is reversed. Your portfolio has a low beta compared to your domestic market index but a high beta compared to a regional market index? This could happen if your domestic market is particularly volatile one year while the rest of the world markets are significantly les ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc so. If your domestic market index is up 35% one year and your portfolio is up 33% the same year, because your beta is less than 1.00, does that still mean that you have a conservative, low-risk portfolio? Investment firms will always tell you a high beta is bad, and that to have higher volatility is a great risk to your por easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi tfolio. If you live somewhere where the stock market index has returned on average 3% for the last five years and has moved within a very narrow range, I would say that to have a low beta is extremely risky because that means that your portfolio is going nowhere, and that if you add in the effects of inflation, your flat por nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically folio has lost purchasing power over those three years. On the other hand, if your portfolio has returned 20% on average over this same time span, your beta will be off the charts. But isn’t a high beta bad? Not at all. If this is the case, then I want my beta to be high, and I want the volatility of my portfolio to be much h and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ gher than the domestic stock market index. Volatility is Not the Same as Risk. Personally I want volatility in many of the stocks I own. If a stock is to return 50% to me in one year, by nature it has to be fairly volatile, because almost no stock just rises steadily higher without experiencing some signifi ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ant corrective actions to the downside. Therefore, stocks with significant gains are going to experience wider fluctuations in their value. It simply is not possible to build wealth without having some huge winners in your portfolio – stocks that have appreciated by 70%, 150%, 350% or even a 1000%. According to the theories p ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a opagated by most investment firms, almost all people that have built substantial wealth through their stock portfolios would have engaged in highly risky behavior. Again, this is just not true. Investors that have huge winners in their portfolios make calculated intelligent decisions to identify asset classes that are poised dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod to boom before the public considers them. They invest at troughs in price and sell when mania sets in, allowing them these huge gains, whereas the average investor will only identify these stocks after everyone else becomes aware of them or some talking head on TV marks it as a screaming buy. Thus, the average investor will cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin nly earn average money from this stock or quite possibly lose money if he or she purchases at the mania phase, while the wealthy investor will have earned phenomenal returns. Absolute Return is All That Matters If you ask most people, they could care less if they had tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen four stocks that lost 40%, 50%, 45% and 55%, if they also owned eight stocks that rose 80%, 100%, 130%, 300%, 287%, 200%, 184%, 65%, and 658%, and their overall return, given the average performance of their remaining portfolio, was 55%. At the end of the day, people only care about the total return of their portfolio. Inves t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ment firms have always stated that such a strategy as risky. If you have stocks that have performed that well, you must be taking huge risks, right? Again this is nonsense. Uncovering volatile stocks that will prove to be huge winners requires time, a commodity that financial consultants do not have as they run their race t ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust gather as many assets as possible. Again, earning these gains is possible without assuming much risk if you perform your due diligence and discover solid assets at rock-bottom prices and invest in them before the general public discovers them. In fact, I would even argue that some stocks that earn 150% or more are less risk y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products than the market stock index at the time I identify them. Why? Because prior to their 150% run up, they were extremely solid companies at extremely cheap prices. Just as I have spoken about dumb diversification versus smart diversification, there is the assumption of dumb volatility versus the assumption of smart volatility. . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de Dumb volatility is chasing penny stocks and pipe dreams of quick returns from companies that spend more money on marketing and PR campaigns to promote their stock than on the operations of the company itself. I have already described above how to add smart volatility to your portfolio. Volatility is not the same as risk as m elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ch as most global investment firms want you to believe this. Again, read my previous blog entry if you’re still not clear as to why this is the case. Low volatility, high diversification, and mediocre returns are a time minimization/ asset gathering maximization sales strategies. Volatility is your friend when building wealth tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Make Friends With The Gatekeeper! 10 Ways to Get Through More Often on the Phone 7 Questions to Ask Yourself Before Joining Any eBay Membership Site - Part Three
|